ABANDONED – EXPRESS AFTER PUB
on 09 Jul 2008
Last Applicant/ Owned by
Glaxo Wellcome House, Berkeley Avenue
Greenford, Middlesex
UB60NN
Serial Number
77167179 filed on 27th Apr 2007
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
ARINIZO
Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmological, respiratory, neurological, gastrointestinal, hormonal, dermatol Read More
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders, and for the treatment of damaged skin and tissue; vaccines
Mark Details
Serial Number
No 77167179
Mark Type
No Service/Collective Mark
Attorney Docket Number
No App/ARINIZO/
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 09th Jul 2008 | ABANDONMENT - AFTER PUBLICATION |
| 09th Jul 2008 | ABANDONMENT NOTICE MAILED - AFTER PUBLICATION |
| 30th Jun 2008 | TEAS EXPRESS ABANDONMENT RECEIVED |
| 03rd Apr 2008 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| 04th Mar 2008 | PUBLISHED FOR OPPOSITION |
| 13th Feb 2008 | NOTICE OF PUBLICATION |
| 29th Jan 2008 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| 29th Jan 2008 | ASSIGNED TO LIE |
| 17th Dec 2007 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 17th Dec 2007 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |